Cargando…

Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer

Although hexokinase (HK) 2, pyruvate kinase muscle (PKM) isozyme 2 and lactate dehydrogenase (LDH) A predict the efficacy of medicines in various solid tumors, their ability to predict the efficacy of cetuximab in metastatic colorectal cancer (mCRC) remains unclear. mCRC patients with pathological s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haohua, Peng, Roujun, Chen, Xiuxing, Jia, Rui, Huang, Chunyue, Huang, Yuanyuan, Xia, Liangping, Guo, Guifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840691/
https://www.ncbi.nlm.nih.gov/pubmed/29552193
http://dx.doi.org/10.3892/ol.2018.8005
_version_ 1783304625442521088
author Wang, Haohua
Peng, Roujun
Chen, Xiuxing
Jia, Rui
Huang, Chunyue
Huang, Yuanyuan
Xia, Liangping
Guo, Guifang
author_facet Wang, Haohua
Peng, Roujun
Chen, Xiuxing
Jia, Rui
Huang, Chunyue
Huang, Yuanyuan
Xia, Liangping
Guo, Guifang
author_sort Wang, Haohua
collection PubMed
description Although hexokinase (HK) 2, pyruvate kinase muscle (PKM) isozyme 2 and lactate dehydrogenase (LDH) A predict the efficacy of medicines in various solid tumors, their ability to predict the efficacy of cetuximab in metastatic colorectal cancer (mCRC) remains unclear. mCRC patients with pathological specimens who received cetuximab and chemotherapy from 2005 to 2015 in the present institution were enrolled. Immunohistochemistry was used to detect HK2, PKM2 and LDHA expression. SPSS20 was used for statistical analysis. A total of 68 patients were included; 33 received cetuximab plus chemotherapy as first-line therapy, and the rest, as second- or later-line therapy. HK2 expression levels were increased in cancer compared with normal tissue (75.4% vs. 40%; P<0.001), however PKM2 (P=0.243) and LDHA (P=0.067) expression levels were not. For progression-free survival (PFS) with first-line cetuximab plus chemotherapy, patients with high HK2 expression exhibited longer PFS compared with those with low HK2 expression (23.9 months vs. 6.9 months; P=0.021). However, this positive association was absent in 35 cases administered first-line chemotherapy alone (13.4 months vs. 13.5 months; P=0.539). LDHA expression was associated with the PFS of patients receiving first-line chemotherapy (18.3 and 10.1 months for high and low expression, respectively; P=0.005), whereas this association was absent in cetuximab plus chemotherapy cases (19.9 months vs. 12 months; P=0.522). Furthermore, high LDHA expression correlated with high overall response rate (ORR) (72.2% vs. 15.4%, P=0.006) for chemotherapy, however not disease control rate (DCR) (P=0.074). Neither DCR nor ORR were associated with HK2 expression. PKM2 expression did not affect PFS, DCR or ORR. LDHA expression (P=0.005), pathological differentiation (P=0.019) and synchronous/metachronous metastasis (P=0.014) were independent predictive factors of PFS for all first-line patients, and tumor differentiation (P=0.002) was associated with overall survival (OS) in multivariate analysis. HK2, PKM2 and LDHA did not impact OS. It was concluded that HK2 expression was increased in colorectal cancer tissue and may predict cetuximab efficacy and LDHA for chemotherapy treatment of mCRC.
format Online
Article
Text
id pubmed-5840691
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-58406912018-03-16 Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer Wang, Haohua Peng, Roujun Chen, Xiuxing Jia, Rui Huang, Chunyue Huang, Yuanyuan Xia, Liangping Guo, Guifang Oncol Lett Articles Although hexokinase (HK) 2, pyruvate kinase muscle (PKM) isozyme 2 and lactate dehydrogenase (LDH) A predict the efficacy of medicines in various solid tumors, their ability to predict the efficacy of cetuximab in metastatic colorectal cancer (mCRC) remains unclear. mCRC patients with pathological specimens who received cetuximab and chemotherapy from 2005 to 2015 in the present institution were enrolled. Immunohistochemistry was used to detect HK2, PKM2 and LDHA expression. SPSS20 was used for statistical analysis. A total of 68 patients were included; 33 received cetuximab plus chemotherapy as first-line therapy, and the rest, as second- or later-line therapy. HK2 expression levels were increased in cancer compared with normal tissue (75.4% vs. 40%; P<0.001), however PKM2 (P=0.243) and LDHA (P=0.067) expression levels were not. For progression-free survival (PFS) with first-line cetuximab plus chemotherapy, patients with high HK2 expression exhibited longer PFS compared with those with low HK2 expression (23.9 months vs. 6.9 months; P=0.021). However, this positive association was absent in 35 cases administered first-line chemotherapy alone (13.4 months vs. 13.5 months; P=0.539). LDHA expression was associated with the PFS of patients receiving first-line chemotherapy (18.3 and 10.1 months for high and low expression, respectively; P=0.005), whereas this association was absent in cetuximab plus chemotherapy cases (19.9 months vs. 12 months; P=0.522). Furthermore, high LDHA expression correlated with high overall response rate (ORR) (72.2% vs. 15.4%, P=0.006) for chemotherapy, however not disease control rate (DCR) (P=0.074). Neither DCR nor ORR were associated with HK2 expression. PKM2 expression did not affect PFS, DCR or ORR. LDHA expression (P=0.005), pathological differentiation (P=0.019) and synchronous/metachronous metastasis (P=0.014) were independent predictive factors of PFS for all first-line patients, and tumor differentiation (P=0.002) was associated with overall survival (OS) in multivariate analysis. HK2, PKM2 and LDHA did not impact OS. It was concluded that HK2 expression was increased in colorectal cancer tissue and may predict cetuximab efficacy and LDHA for chemotherapy treatment of mCRC. D.A. Spandidos 2018-04 2018-02-08 /pmc/articles/PMC5840691/ /pubmed/29552193 http://dx.doi.org/10.3892/ol.2018.8005 Text en Copyright: © Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Wang, Haohua
Peng, Roujun
Chen, Xiuxing
Jia, Rui
Huang, Chunyue
Huang, Yuanyuan
Xia, Liangping
Guo, Guifang
Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer
title Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer
title_full Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer
title_fullStr Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer
title_full_unstemmed Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer
title_short Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer
title_sort effect of hk2, pkm2 and ldha on cetuximab efficacy in metastatic colorectal cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840691/
https://www.ncbi.nlm.nih.gov/pubmed/29552193
http://dx.doi.org/10.3892/ol.2018.8005
work_keys_str_mv AT wanghaohua effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer
AT pengroujun effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer
AT chenxiuxing effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer
AT jiarui effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer
AT huangchunyue effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer
AT huangyuanyuan effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer
AT xialiangping effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer
AT guoguifang effectofhk2pkm2andldhaoncetuximabefficacyinmetastaticcolorectalcancer